Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246673 · ClinicalTrials.gov registry record · Phase 2
RDEA3170 and Febuxostat Combination Study in Gout Subjects
A Phase 2 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02246673: Completed Phase 2 study, sponsored by Ardea Biosciences.
NCT02246673 is a Phase 2 study that has completed, run by Ardea Biosciences. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02246673, a Phase 2 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult subjects with gout.
Primary Outcome
Maximum observed percentage (%) change from baseline in serum urate concentrations.
Interventions
- DRUG RDEA3170 5 mg
- DRUG RDEA3170 10 mg
- DRUG Febuxostat 40 mg
- DRUG RDEA3170 15 mg
- DRUG RDEA3170 2.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
What the finished NCT02246673 record still lists
NCT02246673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 5 interventions - of which RDEA3170 5 mg is the first listed.
NCT02246673 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02246673 about?
NCT02246673 is a clinical study titled "RDEA3170 and Febuxostat Combination Study in Gout Subjects". This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult subjects with gout.
What is the current status of trial NCT02246673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2014-10. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02246673?
The interventions under investigation include: RDEA3170 5 mg (DRUG), RDEA3170 10 mg (DRUG), Febuxostat 40 mg (DRUG), RDEA3170 15 mg (DRUG), RDEA3170 2.5 (DRUG).
Who is sponsoring clinical trial NCT02246673?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02246673's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia